Research shows that antibody levels produced by two shots of the Pfizer-BioNTech vaccine can be reduced by up to 10 times seven months after the second vaccination.
A drop in antibody levels will compromise the body’s ability to defend itself against COVID-19 if the person becomes infected.
In a recent BioRxiv study published before the peer-reviewed vaccine, several recipients of the vaccine displayed a substantial lack of antibodies to the CCP (Communist Party of China) virus, or SARS-CoV-2, and its variants, including delta, beta and mu.
Bali Pulendran of Stanford University and Mehul Suthar of Emory University told Reuters that the study shows that “vaccination with the Pfizer-BioNTech vaccine induces high levels of neutralizing antibodies against the original vaccine strain, but these levels Nearly 10 times less in seven months.”
While the body has other defense mechanisms to ward off the virus, Pulendran and Suthar said antibodies are “critically important in protecting against SARS-CoV-2 infection.”
The study focused on 46 healthy participants who received two doses of the Pfizer-BioEntech vaccine. The participants’ blood was tested once after receiving the second vaccination and again six months later.
The researchers suggested administering a third booster vaccination as a measure to improve vaccine efficacy.
Officials said data from a phase I study reported that participants had higher levels of neutralization antibody titers against the delta version of the CCP virus after receiving a booster—a third dose—versus those who received just two doses, officials said. received, the officials said.
“The third dose increased neutralizing antibodies to 100-fold higher levels in our laboratory studies.” [after the third dose] Compared to [before]Pfizer Chief Scientific Officer Mikel Dolston told investors in a call earlier this year.
According to a July 28 study by companies from scientists, the two-dose Pfizer vaccine was found to be 96 percent effective for the first two months after the second dose.
The research paper outlined a drop in efficacy to 83.7 percent after four to six months.
The Pfizer-BioNTech vaccine is the most widely used vaccine in the United States. As of September 30, more than 226 million doses have been given, versus 151 million from Modern Shots and 15 million from Johnson & Johnson.
This News Originally From – The Epoch Times